In Vitro Susceptibilities of Gram-Negative Bacteria Isolated from Hospitalized Patients in Four European Countries, Canada, and the United States in 2000-2001 to Expanded-Spectrum Cephalosporins and Comparator Antimicrobials: Implications for Therapy

Documents similaires

• Baseline Study To Determine In Vitro Activities of Daptomycin against Gram-Positive Pathogens Isolated in the United States in 2000-2001
  par: Critchley, Ian A., et autres
  Publié: (2003)
• Tracking the implementation of NCCLS M100-S12 expanded-spectrum cephalosporin MIC breakpoints for nonmeningeal isolates of <it>Streptococcus pneumoniae </it>by clinical laboratories in the United States during 2002 and 2003
  par: Thornsberry Clyde, et autres
  Publié: (2004-01-01)
• Tracking the implementation of NCCLS M100-S12 expanded-spectrum cephalosporin MIC breakpoints for nonmeningeal isolates of Streptococcus pneumoniae by clinical laboratories in the United States during 2002 and 2003
  par: Master, Ronald N, et autres
  Publié: (2004)
• Emerging resistance among bacterial pathogens in the intensive care unit – a European and North American Surveillance study (2000–2002)
  par: Jones, Mark E, et autres
  Publié: (2004)
• Determining Linezolid’s Baseline In Vitro Activity in Canada Using Gram-Positive Clinical Isolates Collected prior to Its National Release
  par: Karlowsky, James A., et autres
  Publié: (2002)